These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 9644998)

  • 1. [Apolipoprotein A-II abnormality].
    Takahashi S; Miyamori I
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):24-6. PubMed ID: 9644998
    [No Abstract]   [Full Text] [Related]  

  • 2. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol homeostatic mechanisms in transgenic mice with altered expression of apoproteins A-I, A-II and A-IV.
    Kalopissis AD; Chambaz J
    Int J Tissue React; 2000; 22(2-3):67-78. PubMed ID: 10937356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Apolipoprotein A-II].
    Takata K
    Nihon Rinsho; 2001 Feb; 59 Suppl 2():101-4. PubMed ID: 11351554
    [No Abstract]   [Full Text] [Related]  

  • 5. Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.
    Holvoet P; Danloy S; Deridder E; Lox M; Bernar H; Dhoest A; Collen D
    J Clin Invest; 1998 Jul; 102(2):379-85. PubMed ID: 9664079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of human apolipoprotein A-II in transgenic mice does not increase their susceptibility to insulin resistance and obesity.
    Escolà-Gil JC; Blanco-Vaca F; Julve J
    Diabetologia; 2002 Apr; 45(4):600-1. PubMed ID: 12032642
    [No Abstract]   [Full Text] [Related]  

  • 7. Reference maps of mouse serum acute-phase proteins: changes with LPS-induced inflammation and apolipoprotein A-I and A-II transgenes.
    Wait R; Chiesa G; Parolini C; Miller I; Begum S; Brambilla D; Galluccio L; Ballerio R; Eberini I; Gianazza E
    Proteomics; 2005 Nov; 5(16):4245-53. PubMed ID: 16196095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoA-II versus ApoA-I: two for one is not always a good deal.
    Castellani LW; Lusis AJ
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1870-2. PubMed ID: 11742857
    [No Abstract]   [Full Text] [Related]  

  • 9. [Abnormal apolipoprotein B].
    Kajinami K; Nohara A; Tohdoh Y; Mabuchi H
    Ryoikibetsu Shokogun Shirizu; 1998; (19 Pt 2):27-8. PubMed ID: 9644999
    [No Abstract]   [Full Text] [Related]  

  • 10. Broad-spectrum CC-chemokine blockade by gene transfer inhibits macrophage recruitment and atherosclerotic plaque formation in apolipoprotein E-knockout mice.
    Bursill CA; Choudhury RP; Ali Z; Greaves DR; Channon KM
    Circulation; 2004 Oct; 110(16):2460-6. PubMed ID: 15477414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein A-I, A-II, C-II, and H expression in the developing lung and sex difference in surfactant lipids.
    Provost PR; Boucher E; Tremblay Y
    J Endocrinol; 2009 Mar; 200(3):321-30. PubMed ID: 19106236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment.
    Johnson J; Carson K; Williams H; Karanam S; Newby A; Angelini G; George S; Jackson C
    Circulation; 2005 Mar; 111(11):1422-30. PubMed ID: 15781753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency.
    Jiang XC; Qin S; Qiao C; Kawano K; Lin M; Skold A; Xiao X; Tall AR
    Nat Med; 2001 Jul; 7(7):847-52. PubMed ID: 11433351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E and atherosclerosis: beyond lipid effect.
    Davignon J
    Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):267-9. PubMed ID: 15681305
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance.
    Elbein SC; Chu W; Ren Q; Wang H; Hemphill C; Hasstedt SJ
    Diabetologia; 2002 Jul; 45(7):1026-33. PubMed ID: 12136402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics and molecular biology.
    Chamberlain JC
    Curr Opin Lipidol; 1994 Jun; 5(3):U66-9. PubMed ID: 7952903
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice.
    Park TS; Panek RL; Mueller SB; Hanselman JC; Rosebury WS; Robertson AW; Kindt EK; Homan R; Karathanasis SK; Rekhter MD
    Circulation; 2004 Nov; 110(22):3465-71. PubMed ID: 15545514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo.
    Rotllan N; Ribas V; Calpe-Berdiel L; Martín-Campos JM; Blanco-Vaca F; Escolà-Gil JC
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):e128-32. PubMed ID: 15994442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
    Chiwata T; Aragane K; Fujinami K; Kojima K; Ishibashi S; Yamada N; Kusunoki J
    Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bibliography. Current world literature. Genetics and Molecular Biology.
    Curr Opin Lipidol; 2005 Apr; 16(2):215-41. PubMed ID: 15767862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.